Degenhardt, L. et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 382, 1564–1574 (2013).
Gakidou, E. et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1345–1422 (2017).
Volkow, N. D. et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73, 292–297 (2016).
Groening, J. M. et al. A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: an umbrella review of systematic reviews and meta-analyses. Psychiatry Res. 331, 115626 (2024).
Petrilli, K. et al. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry 9, 736–750 (2022).
Hjorthøj, C. et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol. Med. https://doi.org/10.1017/S0033291723000880 (2023).
Hasan, A. et al. Cannabis use and psychosis: a review of reviews. Eur. Arch. Psychiatry Clin. Neurosci. 270, 403–412 (2020).
Schoeler, T. et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3, 215–225 (2016).
Schoeler, T. et al. Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. JAMA Psychiatry 73, 1173–1179 (2016).
Tarricone, I. et al. The impact of substance use at psychosis onset on first episode psychosis course: results from a 1 year follow-up study in Bologna. Schizophr Res. 153, 60–63 (2014).
Patel, R. et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open 6, e009888 (2016).
Manrique-Garcia, E. et al. Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol. Med. 44, 2513–2521 (2014).
Marijuana Policy Project: state policy. Marijuana Policy Project https://www.mpp.org/states/ (accessed 13 February 2025).
Cerdá, M. et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry 77, 165–171 (2020).
Barret, W. M., Megan, H. R., Claire, E. M. & James, C. A. Estimating the effects of legalizing recreational cannabis on newly incident cannabis use. PLoS ONE https://doi.org/10.1371/journal.pone.0271720 (2022).
Hyatt, A. S., Overhage, L. & Cook, B. L. Use of tobacco and cannabis following state-level cannabis legalization. JAMA Netw Open 8, e2520093 (2025).
Hasin, D. S. et al. State cannabis legalization and cannabis use disorder in the US Veterans Health Administration, 2005 to 2019. JAMA Psychiatry 80, 380–388 (2023).
Hyatt, A. S. et al. Cannabis use among individuals with psychosis after state-level commercial cannabis legalization. JAMA Psychiatry https://doi.org/10.1001/jamapsychiatry.2025.2539 (2025).
Murray, R. M. & Hall, W. Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis? JAMA Psychiatry 77, 777–778 (2020).
Vignault, C. et al. The potential impact of recreational cannabis legalization on the prevalence of cannabis use disorder and psychotic disorders: a retrospective observational study. Can. J. Psychiatry 66, 1069–1076 (2021).
Moran, L. V., Tsang, E. S., Ongur, D., Hsu, J. & Choi, M. Y. Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States. Psychiatry Res. 308, 114387 (2022).
Joshi, S. et al. Changes in psychosis-related emergency department and hospitalization rates among youth following cannabis legalization in Colorado. Drug Alcohol Depend. 273, 112719 (2025).
Elser, H. et al. State cannabis legalization and psychosis-related health care utilization. JAMA Netw Open 6, e2252689 (2023).
Canadian Department of Justice. Cannabis Legalization and Regulation https://www.justice.gc.ca/eng/cj-jp/cannabis/ (2021).
Myran, D. T. et al. Changes in incident schizophrenia diagnoses associated with cannabis use disorder after cannabis legalization. JAMA Netw Open 8, e2457868 (2025).
Callaghan, R. C. et al. Associations between Canada’s cannabis legalization and emergency department presentations for transient cannabis-induced psychosis and schizophrenia conditions: Ontario and Alberta, 2015–2019. Can. J. Psychiatry 67, 616–625 (2022).
Anderson, K. K. et al. Impact of non-medical cannabis legalization with market restrictions on health service use and incident cases of psychotic disorder in Ontario, Canada. Int. J. Drug Policy 123, 104285 (2024).
Kim, C., Bai Y., Cao P., Ienciu K. & Chum A. The impact of recreational cannabis legalization on cannabis-related acute care events among adults with schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. https://doi.org/10.1007/s00127-024-02773-4 (2024).
Myran, D. T., Gaudreault, A., Konikoff, L., Talarico, R. & Liccardo Pacula, R. Changes in cannabis-attributable hospitalizations following nonmedical cannabis legalization in Canada. JAMA Netw Open 6, e2336113 (2023).
Johnson, J. K. & Doonan, S. M. Cannabis policy heterogeneity and effects on research—complexity expected. JAMA Netw Open 4, e212545 (2021).
Dimick, J. B. & Ryan, A. M. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA 312, 2401–2402 (2014).
Olivares, J. M., Sermon, J., Hemels, M. & Schreiner, A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann. Gen. Psychiatry 12, 32 (2013).
Pacula, R. L., Powell, D., Heaton, P. & Sevigny, E. L. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. J. Policy Anal. Manag. 34, 7–31 (2015).
Hawkins, S. S., Baidoo, C. E., Coley, R. L., Centanni, R. S. & Baum, C. F. The impact of recreational cannabis legalization on cannabis use in US Adults from 2016 to 2023: a quasi-experimental study. Am. J. Prev. Med. https://doi.org/10.1016/j.amepre.2025.108221 (2026).
Gilman, J. M. Association of cannabis legalization with prevalence of schizophrenia—challenges of attributing biological causality to policy change. JAMA Netw Open 8, e2457876 (2025).
Myran, D. T. et al. Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis. Mol. Psychiatry 28, 4251–4260 (2023).
Purtle, J., Brinson, K. & Stadnick, N. A. Earmarking excise taxes on recreational cannabis for investments in mental health: an underused financing strategy. JAMA Health Forum 3, e220292 (2022).
Hasin, D. S. et al. Adult use of highly-potent Δ9-THC cannabis concentrate products by US state cannabis legalization status, 2021. Addict. Behav. 140, 107617 (2023).
Di Forti, M. et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6, 427–436 (2019).
Quattrone, D. et al. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study. Psychol. Med. 51, 1329–1337 (2021).
Hjorthøj, C., Posselt, C. M. & Nordentoft, M. Development over time of the population-attributable risk fraction for cannabis use disorder in schizophrenia in Denmark. JAMA Psychiatry 78, 1013–1019 (2021).
Carlini, B. H., Kellum, L. B., Garrett, S. B. & Nims, L. N. Threaten, distract, and discredit: cannabis industry rhetoric to defeat regulation of high-THC cannabis products in Washington State. J. Stud. Alcohol Drugs 85, 322–329 (2024).
Barry, R. A. & Glantz, S. A. Marijuana regulatory frameworks in four US states: an analysis against a public health standard. Am. J. Public Health 108, 914–923 (2018).
Han, B. & Shi, Y. Associations of recreational cannabis dispensaries’ availability, storefront signage and health benefit signs with cannabis use: findings from a representative adult sample in California, United States. Addiction 118, 1270–1279 (2023).
Berg, C. J. et al. Cannabis retailer marketing strategies and regulatory compliance: a surveillance study of retailers in 5 US cities. Addict. Behav. 143, 107696 (2023).
Meek, C. J. et al. Regulatory landscape of cannabis warning labels in US states with legal retail nonmedical cannabis, 2024. Am. J. Public Health 114, S681–S684 (2024).
US Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse & Food and Drug Administration. Population Assessment of Tobacco and Health (PATH) Study [United States] Restricted-Use Files (ICPSR 36231) https://doi.org/10.3886/ICPSR36231.v36 (2023).
McMillan, K. A., Enns, M. W., Cox, B. J. & Sareen, J. Comorbidity of axis I and II mental disorders with schizophrenia and psychotic disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Can. J. Psychiatry 54, 477–486 (2009).
Davis, G. P., Compton, M. T., Wang, S., Levin, F. R. & Blanco, C. Association between cannabis use, psychosis, and schizotypal personality disorder: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr. Res. 151, 197–202 (2013).
Han, B. et al. Tobacco use, nicotine dependence, and cessation methods in US Adults with psychosis. JAMA Netw Open 6, e234995 (2023).
National Institute on Alcohol Abuse and Alcoholism. Alcohol Policy Information System: Recreational use of Cannabis https://alcoholpolicy.niaaa.nih.gov/cannabis-policy-topics/recreational-use-of-cannabis-volume-1/104 (accessed 4 October 2024).
Marijuana Policy Project: state policy; https://www.mpp.org/states/ (accessed 30 August 2024).
Finkelstein, A. The aggregate effects of health insurance: evidence from the introduction of Medicare. Q. J. Econ. 122, 1–37 (2007).
Callaway, B. & Sant’Anna, P. H. C. Difference-in-differences with multiple time periods. J. Econom. 225, 200–230 (2021).
Wing, C., Simon, K. & Bello-Gomez, R. A. Designing difference in difference studies: best practices for public health policy research. Annu. Rev. Public Health 39, 453–469 (2018).
Freyaldenhoven S., Hansen C., Pérez Pérez J., Shapiro J. M. Visualization, Identification, and Estimation in the Linear Panel Event-Study Design; https://doi.org/10.3386/w29170 (National Bureau of Economic Research, 2021).
StataCorp. Stata Statistical Software: Release 19 (StataCorp LLC, 2025).